Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.4B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs relative to its revenue.

$-0.54

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for various conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of $-0.64, which was worse than the expected $-0.55. The stock reacted negatively, declining by 0.19% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another challenging quarter for Cogent, with a consensus EPS estimate of $-0.54. Investors are closely watching for any signs of improvement in financial performance.

Bull Case

If Cogent can exceed EPS expectations and provide positive updates on its drug development pipeline, it could boost investor confidence and lead to a rally in the stock price.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any positive outlook, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs relative to its revenue.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.54?

A smaller loss than expected could indicate improved operational efficiency and boost investor confidence.

Are there any updates on the drug development pipeline that could lead to future revenue?

Positive news on drug development could significantly impact the company's long-term growth prospects and stock valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected loss, as recent operational improvements could lead to better-than-expected results.

Supporting Evidence

The options market is pricing in a significant move, indicating that traders are anticipating volatility that could favor a positive surprise.

Historical trends show that even when the company misses EPS estimates, the stock has often reacted positively in subsequent days.

Key Risk

If the EPS comes in better than $-0.54, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved performance against the backdrop of recent losses and lack of revenue.

Bull Confirmed If

Reporting an EPS loss of less than $-0.54 and providing positive updates on drug development.

Bear Confirmed If

An EPS loss greater than $-0.54 without any positive news on future revenue.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of over 10%, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.3% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats EPS estimates, history suggests the stock could rise by an average of 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 3.44%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the drug development pipeline and timelines for potential approvals.
2Updates on cost management strategies that could improve EPS.
3Insights into partnerships or collaborations that could enhance revenue prospects.
4Discussion of market conditions and competitive landscape impacting future growth.
5Any guidance on expected revenue streams in the coming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs relative to its revenue.

$-0.54

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of $-0.64, which was worse than the expected $-0.55. The stock reacted negatively, declining by 0.19% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another challenging quarter for Cogent, with a consensus EPS estimate of $-0.54. Investors are closely watching for any signs of improvement in financial performance.

Bull Case

If Cogent can exceed EPS expectations and provide positive updates on its drug development pipeline, it could boost investor confidence and lead to a rally in the stock price.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any positive outlook, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs relative to its revenue.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.54?

A smaller loss than expected could indicate improved operational efficiency and boost investor confidence.

Are there any updates on the drug development pipeline that could lead to future revenue?

Positive news on drug development could significantly impact the company's long-term growth prospects and stock valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected loss, as recent operational improvements could lead to better-than-expected results.

Supporting Evidence

The options market is pricing in a significant move, indicating that traders are anticipating volatility that could favor a positive surprise.

Historical trends show that even when the company misses EPS estimates, the stock has often reacted positively in subsequent days.

Key Risk

If the EPS comes in better than $-0.54, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved performance against the backdrop of recent losses and lack of revenue.

Bull Confirmed If

Reporting an EPS loss of less than $-0.54 and providing positive updates on drug development.

Bear Confirmed If

An EPS loss greater than $-0.54 without any positive news on future revenue.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of over 10%, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.3% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats EPS estimates, history suggests the stock could rise by an average of 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 3.44%, reflecting ongoing concerns about profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the drug development pipeline and timelines for potential approvals.
2Updates on cost management strategies that could improve EPS.
3Insights into partnerships or collaborations that could enhance revenue prospects.
4Discussion of market conditions and competitive landscape impacting future growth.
5Any guidance on expected revenue streams in the coming quarters.